Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis

被引：3

作者：

Arigami, Takaaki ^{[1
]}

Matsushita, Daisuke ^{[2
]}

Okubo, Keishi ^{[2
]}

Sasaki, Ken ^{[2
]}

Tsuruda, Yusuke ^{[2
]}

Kita, Yoshiaki ^{[2
]}

Mori, Shinichiro ^{[2
]}

Yanagita, Shigehiro ^{[2
]}

Uenosono, Yoshikazu ^{[2
]}

Kurahara, Hiroshi ^{[2
]}

Ohtsuka, Takao ^{[1
,2
]}

机构：

[1] Kagoshima Univ, Dept Oncobiol Surg, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan

[2] Kagoshima Univ, Dept Digest Surg Breast & Thyroid Surg, Grad Sch Med & Dent Sci, Kagoshima, Japan

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 06期

关键词：

Gastric cancer; para-aortic lymph node metastasis; trastuzumab; prognosis; HER2; expression; NEOADJUVANT CHEMOTHERAPY; LARGE-SCALE; MULTICENTER; CISPLATIN; SURVIVAL; IMPACT; S-1;

D O I：

10.21873/anticanres.15094

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To determine the prognostic utility of trastuzumab-based chemotherapy based on human epidermal growth factor receptor 2 (HER2) expression in patients with para-aortic lymph node (PAN) metastasis from gastric cancer. Patients and Methods: A total of 41 patients with clinical PAN metastasis from gastric cancer who underwent chemotherapy were retrospectively enrolled. Results: Eighteen (43.9%) patients had HER2-positive tumors and consequently, received trastuzumab-based chemotherapy. A total of 11 patients underwent surgery. HER2 status was significantly correlated with the number of distant metastatic sites, the presence or absence of trastuzumab-based chemotherapy, and the presence or absence of gastrectomy. HER2-positive patients had significantly better prognosis than HER2-negative patients. Multivariate analysis identified age and trastuzumab-based chemotherapy based on HER2 status as an independent prognostic factor. Conclusion: Assessing HER2 expression and subsequent trastuzumab-based chemotherapy can be an effective method for determining the prognosis of patients with PAN metastasis from gastric cancer.

引用

页码：3099 / 3107

页数：9

共 26 条

[1] Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population [J].

Aizawa, Masaki ;

Nagatsuma, Akiko K. ;

Kitada, Koji ;

Kuwata, Takeshi ;

Fujii, Satoshi ;

Kinoshita, Taira ;

Ochiai, Atsushi .

GASTRIC CANCER, 2014, 17 (01) :34-42

[2]

Amin MB, AJCC Cancer Staging Manual

[3] Clinical Significance of Conversion Surgery for Gastric Cancer with Peritoneal Dissemination: A Retrospective Study [J].

Arigami, Takaaki ;

Matsushita, Daisuke ;

Okubo, Keishi ;

Sasaki, Ken ;

Noda, Masahiro ;

Kita, Yoshiaki ;

Mori, Shinichiro ;

Kurahara, Hiroshi ;

Yanagita, Shigehiro ;

Uenosono, Yoshikazu ;

Ishigami, Sumiya ;

Ohtsuka, Takao ;

Natsugoe, Shoji .

ONCOLOGY, 2020, 98 (11) :798-806

[4] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6] Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202 [J].

Endo, Shunji ;

Kurokawa, Yukinori ;

Gamoh, Makio ;

Kimura, Yutaka ;

Matsuyama, Jin ;

Taniguchi, Hirokazu ;

Takeno, Atsushi ;

Kawabata, Ryohei ;

Kawada, Junji ;

Masuzawa, Toru ;

Yamamoto, Kazuyoshi ;

Kobayashi, Kouji ;

Sakai, Daisuke ;

Shimokawa, Toshio ;

Satoh, Taroh .

ANTICANCER RESEARCH, 2019, 39 (02) :1059-1065

[7] Review article: the epidemiology and prevention of gastric cancer [J].

Fock, K. M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (03) :250-260

[8] A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A) [J].

Fukagawa, Takeo ;

Katai, Hitoshi ;

Mizusawa, Junki ;

Nakamura, Kenichi ;

Sano, Takeshi ;

Terashima, Masanori ;

Ito, Seiji ;

Yoshikawa, Takaki ;

Fukushima, Norimasa ;

Kawachi, Yasuyuki ;

Kinoshita, Takahiro ;

Kimura, Yutaka ;

Yabusaki, Hiroshi ;

Nishida, Yasunori ;

Iwasaki, Yoshiaki ;

Lee, Sang-Woong ;

Yasuda, Takashi ;

Sasako, Mitsuru .

GASTRIC CANCER, 2018, 21 (01) :68-73

[9] Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients [J].

Fuse, Nozomu ;

Kuboki, Yasutoshi ;

Kuwata, Takeshi ;

Nishina, Tomohiro ;

Kadowaki, Shigenori ;

Shinozaki, Eiji ;

Machida, Nozomu ;

Yuki, Satoshi ;

Ooki, Akira ;

Kajiura, Shinya ;

Kimura, Tetsuo ;

Yamanaka, Takeharu ;

Shitara, Kohei ;

Nagatsuma, Akiko Kawano ;

Yoshino, Takayuki ;

Ochiai, Atsushi ;

Ohtsu, Atsushi .

GASTRIC CANCER, 2016, 19 (01) :183-191

[10] HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J].

Gravalos, C. ;

Jimeno, A. .

ANNALS OF ONCOLOGY, 2008, 19 (09) :1523-1529

← 1 2 3 →